Fierce JPM Week: Bristol Myers’ next-gen autoimmune med not just another JAK drug, exec says

Fierce JPM Week: Bristol Myers’ next-gen autoimmune med not just another JAK drug, exec says
esagonowsky
Fri, 01/21/2022 – 11:04